

**ERIVEDGE Capsules 150 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025**SECTION 1. IDENTIFICATION**

Product name : ERIVEDGE Capsules 150 mg

Product code : RO545-0815/F03-00

Common name(s),  
synonym(s) of the substance : ERIVEDGE Capsules 150 mg**Manufacturer or supplier's details**

Company name of supplier : Genentech, Inc.

Address : 1 DNA Way  
South San Francisco, CA 94080  
USA

Telephone : 001-(650) 225-1000

E-mail address : info.sds@roche.com

Emergency telephone

In case of emergencies: : US CHEMTREC PHONE (800)-424-9300

**Recommended use of the chemical and restrictions on use**

Recommended use : Formulated pharmaceutical active substance

Restrictions on use : For professional users only.

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)**

Carcinogenicity : Category 2

Reproductive toxicity : Category 1B

Specific target organ toxicity : Category 2  
- repeated exposure**GHS label elements**

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H351 Suspected of causing cancer.  
H360FD May damage fertility. May damage the unborn child.  
H373 May cause damage to organs through prolonged or repeated exposure.

**ERIVEDGE Capsules 150 mg**
Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

Precautionary Statements : **Prevention:**

P201 Obtain special instructions before use.  
 P202 Do not handle until all safety precautions have been read and understood.  
 P260 Do not breathe dust.  
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards**

None known.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Vismodegib	879085-55-9	35.29
Cellulose	9004-34-6	20.54
Gelatins	9000-70-8	17.51
Lactose-1-Hydrate	64044-51-5	16.82
Starch, carboxymethyl ether, sodium salt	9063-38-1	4.12
2-Pyrrolidinone, 1-ethenyl-, homopolymer	9003-39-8	2.47
Sulfuric acid monododecyl ester sodium salt (1:1)	151-21-3	1.65
Talc (Mg <sub>3</sub> H <sub>2</sub> (SiO <sub>3</sub> ) <sub>4</sub> )	14807-96-6	0.82
Octadecanoic acid, magnesium salt (2:1)	557-04-0	0.4
Titanium oxide (TiO <sub>2</sub> )	13463-67-7	0.35
Iron oxide (Fe <sub>3</sub> O <sub>4</sub> )	1317-61-9	0.02
Iron oxide (Fe <sub>2</sub> O <sub>3</sub> )	1309-37-1	0.01

**SECTION 4. FIRST AID MEASURES**

General advice : Move out of dangerous area.  
 Show this material safety data sheet to the doctor in attendance.  
 Do not leave the victim unattended.

**ERIVEDGE Capsules 150 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

If inhaled : If unconscious, place in recovery position and seek medical advice.  
If symptoms persist, call a physician.

In case of skin contact : If skin irritation persists, call a physician.  
If on skin, rinse well with water.  
If on clothes, remove clothes.

In case of eye contact : Flush eyes with water as a precaution.  
Remove contact lenses.  
Protect unharmed eye.  
Keep eye wide open while rinsing.  
If eye irritation persists, consult a specialist.

If swallowed : Induce vomiting immediately and call a physician.  
Keep respiratory tract clear.  
Do not give milk or alcoholic beverages.  
Never give anything by mouth to an unconscious person.  
If symptoms persist, call a physician.  
Take victim immediately to hospital.

Most important symptoms and effects, both acute and delayed : Suspected of causing cancer.  
May damage fertility. May damage the unborn child.  
May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection and use the recommended protective clothing

Notes to physician : Treat symptomatically.

---

**SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media : High volume water jet

Specific hazards during fire fighting : Do not allow run-off from fire fighting to enter drains or water courses.

Hazardous combustion products : Gaseous hydrogen chloride (HCl).  
Sulfur oxides  
Nitrogen oxides (NOx)  
Carbon oxides  
Sodium oxides

Further information : Collect contaminated fire extinguishing water separately. This must not be discharged into drains.  
Fire residues and contaminated fire extinguishing water must

**ERIVEDGE Capsules 150 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

be disposed of in accordance with local regulations.

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

---

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures : Prevent any exposure  
Use personal protective equipment.  
Avoid dust formation.  
Avoid breathing dust.  
Refer to protective measures listed in sections 7 and 8.

Environmental precautions : Prevent product from entering drains.  
Prevent further leakage or spillage if safe to do so.  
If the product contaminates rivers and lakes or drains inform respective authorities.

Methods and materials for containment and cleaning up : Keep in suitable, closed containers for disposal.

---

**SECTION 7. HANDLING AND STORAGE**

Advice on protection against fire and explosion : Avoid dust formation.  
Provide appropriate exhaust ventilation at places where dust is formed.

Advice on safe handling : Avoid formation of respirable particles.  
Do not breathe vapors/dust.  
Avoid exposure - obtain special instructions before use.  
Avoid contact with skin and eyes.  
For personal protection see section 8.  
Smoking, eating and drinking should be prohibited in the application area.  
Dispose of rinse water in accordance with local and national regulations.

Conditions for safe storage : Keep container tightly closed in a dry and well-ventilated place.  
Containers which are opened must be carefully resealed and kept upright to prevent leakage.  
Electrical installations / working materials must comply with the technological safety standards.

Storage temperature : 15 °C to 30 °C  
Protect against light.  
Protect from moisture.

Further information on storage stability : No decomposition if stored and applied as directed.

**ERIVEDGE Capsules 150 mg**
Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

Packaging material : Suitable material: Plastic container of HDPE, Polyethylene bag in metal drum, Stainless steel, glass

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**
**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Vismodegib	879085-55-9	IOEL	0.0003 mg/m <sup>3</sup>	Roche Industrial Hygiene Committee (RIHC)
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable)	5 mg/m <sup>3</sup>	NIOSH REL
		TWA (total)	10 mg/m <sup>3</sup>	NIOSH REL
		TWA (total dust)	15 mg/m <sup>3</sup>	OSHA Z-1
		TWA (respirable fraction)	5 mg/m <sup>3</sup>	OSHA Z-1
		TWA (Total dust)	15 mg/m <sup>3</sup>	OSHA P0
		TWA (respirable dust fraction)	5 mg/m <sup>3</sup>	OSHA P0
Titanium oxide (TiO <sub>2</sub> )	13463-67-7	TWA (total dust)	15 mg/m <sup>3</sup>	OSHA Z-1
		TWA (Total dust)	10 mg/m <sup>3</sup>	OSHA P0
		TWA (Respirable particulate matter)	0.2 mg/m <sup>3</sup> (Titanium dioxide)	ACGIH
		TWA (Respirable particulate matter)	2.5 mg/m <sup>3</sup> (Titanium dioxide)	ACGIH
Substance name	Environmental Compartment		Value	
Vismodegib	Surface waters		9.2 µg/l	
	Remarks: Based on acute data			
sodium dodecyl sulphate	Fresh water		0.176 mg/l	
	Sea water		0.0176 mg/l	
	Fresh water sediment		6.97 mg/kg	
	Sea sediment		0.697 mg/kg	
	Soil		1.29 mg/kg	

Engineering measures : No data available

**ERIVEDGE Capsules 150 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025**Personal protective equipment**

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

Material : In case of contact through splashing:  
Break through time : Nitrile rubber  
Glove thickness : > 30 min  
: > 0.11 mm

Material : In case of full contact:  
Break through time : butyl-rubber  
Glove thickness : > 480 min  
: > 0.4 mm

Remarks : Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly.

Eye protection : Eye wash bottle with pure water  
: Tightly fitting safety goggles

Skin and body protection : Choose body protection according to the amount and concentration of the dangerous substance at the work place.

Protective measures : Instruction of employees mandatory

Hygiene measures : When using do not eat or drink.  
: When using do not smoke.  
: Wash hands before breaks and at the end of workday.

---

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : capsules

Color : gray

pink

Odor : Not applicable

**ERIVEDGE Capsules 150 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

Odor Threshold	:	Not applicable
pH	:	Not applicable
Melting point/ range	:	No data available
Boiling point/boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Self-ignition	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Solubility in other solvents	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, dynamic	:	Not applicable
Viscosity, kinematic	:	Not applicable
Explosive properties	:	No data available
Oxidizing properties	:	No data available
Particle characteristics		
Particle Size Distribution	:	No data available

**ERIVEDGE Capsules 150 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	: No dangerous reaction known under conditions of normal use.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: No decomposition if stored and applied as directed.
Conditions to avoid	: No data available
Incompatible materials	: Not applicable
Hazardous decomposition products	: No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION****Acute toxicity**

Not classified due to lack of data.

**Product:**

Acute oral toxicity	: Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
Acute inhalation toxicity	: Acute toxicity estimate: 63.49 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: Calculation method
Acute dermal toxicity	: Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method

**Components:****Vismodegib:**

Acute oral toxicity	: LD50 Oral (Rat): > 2,000 mg/kg Method: OECD Test Guideline 423 GLP: yes
---------------------	---

**Cellulose:**

Acute oral toxicity	: LD50 Oral (Rat): > 5,000 mg/kg
Acute dermal toxicity	: LD50 Dermal (Rabbit): > 2,000 mg/kg

**Lactose-1-Hydrate:**

**ERIVEDGE Capsules 150 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

Acute oral toxicity : LD50 Oral (Rat): > 10,000 mg/kg  
Test substance: anhydrous substance

**Sulfuric acid monododecyl ester sodium salt (1:1):**

Acute oral toxicity : LD50 Oral (Rat, male and female): 1,200 mg/kg  
Method: OECD Test Guideline 401

Acute inhalation toxicity : Assessment: The component/mixture is moderately toxic after short term inhalation.

Acute dermal toxicity : LD50 Dermal (Rat, male and female): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
GLP: yes  
Remarks: No mortality observed at this dose.

**Titanium oxide (TiO<sub>2</sub>):**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Method: OECD Test Guideline 425

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

**Skin corrosion/irritation**

Not classified due to lack of data.

**Product:**

Remarks : May cause skin irritation and/or dermatitis.

**Components:****Vismodegib:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation  
GLP : yes

**Sulfuric acid monododecyl ester sodium salt (1:1):**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : Irritating to skin.

**ERIVEDGE Capsules 150 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

GLP : no

**Titanium oxide (TiO2):**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

**Serious eye damage/eye irritation**

Not classified due to lack of data.

**Product:**

Remarks : Product dust may be irritating to eyes, skin and respiratory system.

**Components:****Sulfuric acid monododecyl ester sodium salt (1:1):**

Species : Rabbit  
Result : Risk of serious damage to eyes.  
Method : OECD Test Guideline 405  
GLP : no

**Titanium oxide (TiO2):**

Species : Rabbit  
Result : No eye irritation  
Method : OECD Test Guideline 405

**Respiratory or skin sensitization****Skin sensitization**

Not classified due to lack of data.

**Respiratory sensitization**

Not classified due to lack of data.

**Components:****Sulfuric acid monododecyl ester sodium salt (1:1):**

Result : Did not cause sensitization on laboratory animals.

**Titanium oxide (TiO2):**

Species : Guinea pig  
Assessment : Does not cause skin sensitization.  
Method : OECD Test Guideline 406

**ERIVEDGE Capsules 150 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025**Germ cell mutagenicity**

Not classified due to lack of data.

**Components:****Vismodegib:**

Genotoxicity in vitro : Test Type: Ames test  
Method: Mutagenicity (Salmonella typhimurium - reverse mutation assay)  
Result: negative  
GLP: yes

Test Type: Chromosome aberration test in vitro  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Rat  
Application Route: Oral  
Result: negative

**Sulfuric acid monododecyl ester sodium salt (1:1):**

Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test)  
Method: OECD Test Guideline 471  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Method: OECD Test Guideline 474  
Result: negative

**Carcinogenicity**

Suspected of causing cancer.

**Components:****Cellulose:**

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**Titanium oxide (TiO2):**

Carcinogenicity - Assessment : Limited evidence of a carcinogenic effect.

**IARC**Group 2B: Possibly carcinogenic to humans  
Titanium oxide (TiO2)

13463-67-7

**OSHA**

No component of this product present at levels greater than or equal to 0.1% is

**ERIVEDGE Capsules 150 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

**Reproductive toxicity**

May damage fertility. May damage the unborn child.

**Components:****Vismodegib:**

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Embryo-fetal toxicity.: LOEL: 10 mg/kg bw/day  
Result: Teratogenicity and developmental toxicity  
GLP: yes

Reproductive toxicity - Assessment : Presumed human reproductive toxicant, May damage fertility.  
May damage the unborn child.

**STOT-single exposure**

Not classified due to lack of data.

**Components:****Sulfuric acid monododecyl ester sodium salt (1:1):**

Routes of exposure : Inhalation  
Target Organs : Respiratory Tract  
Assessment : May cause respiratory irritation.

**STOT-repeated exposure**

May cause damage to organs through prolonged or repeated exposure.

**Components:****Vismodegib:**

Assessment : May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Vismodegib:**

Species : Rat  
NOAEL : <5 mg/kg/w  
Application Route : Oral  
Exposure time : 26 Weeks

Species : Mouse  
NOAEL : 50 mg/kg bw/day  
Application Route : Oral  
Exposure time : 84 d  
Remarks : Subchronic toxicity

**ERIVEDGE Capsules 150 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025**Aspiration toxicity**

Not classified due to lack of data.

**Further information****Product:**

Remarks : No data available

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Vismodegib:**

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 1.5 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
GLP: yes

NOEC (Danio rerio (zebra fish)): 1.5 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
GLP: yes

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h  
Test Type: Immobilization  
Analytical monitoring: yes  
Method: OECD Test Guideline 202  
GLP: yes  
Remarks: nominal concentration

NOEC (Daphnia magna (Water flea)): 0.85 mg/l  
Exposure time: 48 h  
Test Type: Immobilization  
Analytical monitoring: yes  
Method: OECD Test Guideline 202  
GLP: yes  
Remarks: average measured concentration

Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (algae)): 0.118 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
GLP: yes

EyC50 (Pseudokirchneriella subcapitata (algae)): 0.099 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
GLP: yes

NOEC (Pseudokirchneriella subcapitata (algae)): 0.069 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

**ERIVEDGE Capsules 150 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025GLP: yes  
Remarks: nominal concentrationErC50 (Desmodesmus subspicatus (green algae)): 0.95 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
GLP: yes  
Remarks: nominal concentrationEyC50 (Desmodesmus subspicatus (green algae)): 0.52 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
GLP: yes  
Remarks: nominal concentrationNOEC (Desmodesmus subspicatus (green algae)): 0.32 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
GLP: yes  
Remarks: nominal concentrationToxicity to daphnia and other  
aquatic invertebrates  
(Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 1.5 mg/l  
Exposure time: 21 d  
Analytical monitoring: yes  
Method: OECD Test Guideline 211  
GLP: yes  
Remarks: nominal concentrationLowest Observed Effect Concentration (Daphnia magna  
(Water flea)): 1.5 mg/l  
Exposure time: 21 d  
Analytical monitoring: yes  
Method: OECD Test Guideline 211  
GLP: yes  
Remarks: nominal concentrationToxicity to microorganisms : (activated sludge): 54 mg/l  
Exposure time: 14 d  
Remarks: no adverse influence on substrate biodegradation  
nominal concentration**Cellulose:****Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

**Lactose-1-Hydrate:****Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

**ERIVEDGE Capsules 150 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

**Sulfuric acid monododecyl ester sodium salt (1:1):**Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 3.6 mg/l  
Exposure time: 96 hToxicity to daphnia and other aquatic invertebrates : EC50 (Ceriodaphnia dubia (water flea)): 5.55 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): > 1.36 mg/l  
Exposure time: 42 dToxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Ceriodaphnia dubia (water flea)): 0.88 mg/l  
Exposure time: 7 dToxicity to microorganisms : EC0 (Pseudomonas putida): > 100 mg/l  
Method: OECD Test Guideline 209**Titanium oxide (TiO<sub>2</sub>):**Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 1,000 mg/l  
Exposure time: 96 h  
Test Type: static testLC50 (Cyprinodon variegatus (sheepshead minnow)): > 10,000 mg/l  
Exposure time: 96 h  
Test Type: semi-static test  
Method: OECD Test Guideline 203Toxicity to daphnia and other aquatic invertebrates : LC50 (Daphnia magna (Water flea)): > 1,000 mg/l  
Exposure time: 48 h  
Test Type: static test  
Method: OECD Test Guideline 202Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l  
Exposure time: 72 h  
Test Type: static test  
Method: OECD Test Guideline 201EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l  
Exposure time: 72 h  
Method: ISO 10253NOEC (Skeletonema costatum (marine diatom)): 5,600 mg/l  
Exposure time: 72 h  
Method: ISO 10253

**ERIVEDGE Capsules 150 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025**Ecotoxicology Assessment**

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

**Persistence and degradability****Components:****Vismodegib:**Biodegradability : aerobic  
Inoculum: activated sludge, non-adapted  
Theoretical oxygen demand  
Result: Not readily biodegradable.  
Exposure time: 28 d  
Method: OECD Test Guideline 301F  
GLP: yes**Lactose-1-Hydrate:**

Biodegradability : Remarks: No data available

**Sulfuric acid monododecyl ester sodium salt (1:1):**Biodegradability : aerobic  
Inoculum: activated sludge, non-adapted  
Result: Readily biodegradable.  
Biodegradation: 95 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301B  
GLP: yes**Titanium oxide (TiO2):**

Biodegradability : Remarks: Not applicable

**Bioaccumulative potential****Components:****Vismodegib:**Partition coefficient: n-octanol/water : log Pow: 1.59  
Method: OECD Test Guideline 117  
GLP: yes**Cellulose:**

Partition coefficient: n-octanol/water : Remarks: No data available

**Lactose-1-Hydrate:**

Bioaccumulation : Remarks: No data available

Partition coefficient: n- : log Pow: -5.01

# SAFETY DATA SHEET

**Genentech**  
A Member of the Roche Group

## **ERIVEDGE Capsules 150 mg**

Version Revision Date: Date of last issue: -  
1.0 06/13/2025 Date of first issue: 06/13/2025

## Sulfuric acid monododecyl ester sodium salt (1:1):

Bioaccumulation : Species: *Cyprinus carpio* (Carp)  
Bioconcentration factor (BCF): 3.9 - 5.3  
Exposure time: 3 d

Partition coefficient: n-octanol/water : log Pow: -2.03 (68 °F / 20 °C)  
Method: OECD Test Guideline 107

## Titanium oxide (TiO<sub>2</sub>):

Partition coefficient: n-octanol/water : Remarks: No data available

## Mobility in soil

## Components:

**Vismodegib:**  
Distribution among environmental compartments : Koc method  
Medium: Soil  
Koc: 2129 - 5001 ml/g  
Method: OECD Test Guideline 106  
Remarks: Slightly mobile in soils

Koc method  
Medium: Sludge  
Koc: 684 - 895 ml/g  
Method: OECD Test Guideline 106

## Other adverse effects

**Product:**

Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances  
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

Additional ecological information : An environmental hazard cannot be excluded in the event of unprofessional handling or disposal.  
Very toxic to aquatic life with long lasting effects.

---

## SECTION 13. DISPOSAL CONSIDERATIONS

## Disposal methods

Waste from residues : The product should not be allowed to enter drains, water courses or the soil.  
Do not contaminate ponds, waterways or ditches with chemical or used container.

**ERIVEDGE Capsules 150 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

Send to a licensed waste management company.

Contaminated packaging : Empty remaining contents.  
Dispose of as unused product.  
Do not re-use empty containers.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)-benzamide)  
Class : 9  
Packing group : III  
Labels : 9  
Environmentally hazardous : no

**IATA-DGR**

UN/ID No. : UN 3077  
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.  
(2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)-benzamide)  
Class : 9  
Packing group : III  
Labels : Class 9 - Miscellaneous dangerous substances and articles  
Packing instruction (cargo aircraft) : 956  
Packing instruction (passenger aircraft) : 956  
Environmentally hazardous : yes

**IMDG-Code**

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)-benzamide)  
Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable

**Domestic regulation****49 CFR**

UN/ID/NA number : UN 3077  
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.  
(2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-

**ERIVEDGE Capsules 150 mg**
Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

Chemical name: (methylsulfonyl)-benzamide  
 Class: 9  
 Packing group: III  
 Labels: Class 9 - Miscellaneous dangerous substances and articles  
 ERG Code: 171  
 Marine pollutant: no

**Special precautions for user**

Remarks: No data available

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**SECTION 15. REGULATORY INFORMATION****CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

**SARA 304 Extremely Hazardous Substances Reportable Quantity**

This material does not contain any components with a section 304 EHS RQ.

**SARA 302 Extremely Hazardous Substances Threshold Planning Quantity**

Components	CAS-No.	Component TPQ (lbs)
<b>SARA 311/312 Hazards</b>	: Carcinogenicity Reproductive toxicity Specific target organ toxicity (single or repeated exposure)	

**Clean Air Act**

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCMI Intermediate or Final VOC's (40 CFR 60.489).

**Clean Water Act**

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

**US State Regulations****Massachusetts Right To Know**

Cellulose	9004-34-6
-----------	-----------

**Pennsylvania Right To Know**

Vismodegib	879085-55-9
Cellulose	9004-34-6

**ERIVEDGE Capsules 150 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

Gelatins	9000-70-8
Lactose-1-Hydrate	64044-51-5
Starch, carboxymethyl ether, sodium salt	9063-38-1

**Maine Chemicals of High Concern****Vermont Chemicals of High Concern****Washington Chemicals of High Concern****California Prop. 65**

WARNING: This product can expose you to chemicals including Titanium oxide (TiO2), which is/are known to the State of California to cause cancer, and Vismodegib, which is/are known to the State of California to cause birth defects or other reproductive harm. For more information go to [www.P65Warnings.ca.gov](http://www.P65Warnings.ca.gov).

**California List of Hazardous Substances**

2-Pyrrolidinone, 1-ethenyl-, homopolymer	9003-39-8
--	-----------

**California Permissible Exposure Limits for Chemical Contaminants**

Cellulose	9004-34-6
-----------	-----------


**The ingredients of this product are reported in the following inventories:**

AIIC	: Not in compliance with the inventory
DSL	: This product contains the following components that are not on the Canadian DSL nor NDSL.  Vismodegib
NZIoC	: Not in compliance with the inventory
ENCS	: Not in compliance with the inventory
ISHL	: Not in compliance with the inventory
KECI	: Not in compliance with the inventory
PICCS	: Not in compliance with the inventory
IECSC	: Not in compliance with the inventory
TCSI	: Not in compliance with the inventory
TSCA	: Product contains substance(s) not listed on TSCA inventory.
TECI	: Not in compliance with the inventory

**TSCA list**

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

**ERIVEDGE Capsules 150 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025**SECTION 16. OTHER INFORMATION****Further information****NFPA 704:****HMIS® IV:**

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

**Full text of other abbreviations**

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA P0	:	USA. Table Z-1-A Limits for Air Contaminants (1989 vacated values)
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA P0 / TWA	:	8-hour time weighted average
OSHA Z-1 / TWA	:	8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test

**ERIVEDGE Capsules 150 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

The GHS classification for skin irritation and/or sensitization of the pure ingredients causes a corresponding GHS classification for the whole formulation. In view of the nature of the formulated product (film-coated tablet, capsule, etc.), an over-interpretation of the potential hazard is possible.

Revision Date : 06/13/2025

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / EN / 2404